Loading
Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery.
Dean Bajorin was principal investigator of CheckMate 274, the trial showing adjuvant nivolumab improves disease-free survival in muscle-invasive urothelial cancer after radical surgery, the first adjuvant immunotherapy approval in the disease. He developed the Bajorin prognostic model for metastatic urothelial cancer and led decades of chemotherapy trials at MSKCC.
Shares PD-1, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
Shares PD-1, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
Shares Memorial Sloan Kettering Cancer Center, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tags urothelial, immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tags adjuvant, immunotherapy.
Shares Memorial Sloan Kettering Cancer Center, Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tags adjuvant, immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.